Ann Oncol:疾病稳定晚期NSCLC患者获益于厄洛替尼维持治疗

2011-06-01 MedSci原创 MedSci原创

     Ann Oncol 5月24日在线发表的一项研究结果显示,接受铂类为基础双药化疗后疾病稳定(SD)的晚期非小细胞肺癌(NSCLC)患者,可显著获益于厄洛替尼维持治疗。   经过4个周期的铂类为基础的双药化疗后,无疾病进展(PD)的患者随机接受厄洛替尼(150 mg/d)或安慰剂治疗,直至PD或出现不可接受的毒性。   一线化疗之后,889例非PD患者被纳入意向性治疗人群[55%SD

  inserted image

  Ann Oncol 5月24日在线发表的一项研究结果显示,接受铂类为基础双药化疗后疾病稳定(SD)的晚期非小细胞肺癌(NSCLC)患者,可显著获益于厄洛替尼维持治疗。

  经过4个周期的铂类为基础的双药化疗后,无疾病进展(PD)的患者随机接受厄洛替尼(150 mg/d)或安慰剂治疗,直至PD或出现不可接受的毒性。

  一线化疗之后,889例非PD患者被纳入意向性治疗人群[55%SD,44%完全缓解(CR) /部分缓解(PR),<1%未知缓解情况]。厄洛替尼维持治疗显著延长SD[危险比(HR)=0.68, P<0.0001]和CR/PR(HR=0.74,P=0.0059)组的无进展生存期(PFS),但仅SD组的OS显著延长(HR=0.72,P=0.0019)。不管肿瘤组织学和/或EGFR突变状态如何,SD组厄洛替尼相关OS益处覆盖各亚组。不良反应事件发生率在SD组和这个群体中相似,埃罗替尼治疗对患者生活质量未产生负面影响。

  相关链接:Survival benefit with erlotinib maintenance therapy in patients with advanced non-small-cell lung cancer (NSCLC) according to response to first-line chemotherapy

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1864331, encodeId=5dff1864331dc, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Fri Sep 09 06:20:00 CST 2011, time=2011-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2068914, encodeId=a69720689146d, content=<a href='/topic/show?id=bbd816043f2' target=_blank style='color:#2F92EE;'>#SCLC患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16043, encryptionId=bbd816043f2, topicName=SCLC患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Sat Jan 21 05:20:00 CST 2012, time=2012-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1332052, encodeId=7033133205207, content=<a href='/topic/show?id=f19136915a9' target=_blank style='color:#2F92EE;'>#厄洛替尼#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36915, encryptionId=f19136915a9, topicName=厄洛替尼)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/6F20312C71B4B22F603078C6DCFA72CE/100, createdBy=d3572500071, createdName=ms306040998833292, createdTime=Fri Jun 03 13:20:00 CST 2011, time=2011-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1410772, encodeId=64241410e728f, content=<a href='/topic/show?id=a4ed130e7d0' target=_blank style='color:#2F92EE;'>#NSCLC患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13077, encryptionId=a4ed130e7d0, topicName=NSCLC患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=06332789533, createdName=xiongliangxl, createdTime=Fri Jun 03 13:20:00 CST 2011, time=2011-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1416240, encodeId=7fbd14162407f, content=<a href='/topic/show?id=6cef59801ea' target=_blank style='color:#2F92EE;'>#晚期NSCLC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59801, encryptionId=6cef59801ea, topicName=晚期NSCLC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3b093156350, createdName=经常头晕, createdTime=Fri Jun 03 13:20:00 CST 2011, time=2011-06-03, status=1, ipAttribution=)]
    2011-09-09 minlingfeng
  2. [GetPortalCommentsPageByObjectIdResponse(id=1864331, encodeId=5dff1864331dc, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Fri Sep 09 06:20:00 CST 2011, time=2011-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2068914, encodeId=a69720689146d, content=<a href='/topic/show?id=bbd816043f2' target=_blank style='color:#2F92EE;'>#SCLC患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16043, encryptionId=bbd816043f2, topicName=SCLC患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Sat Jan 21 05:20:00 CST 2012, time=2012-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1332052, encodeId=7033133205207, content=<a href='/topic/show?id=f19136915a9' target=_blank style='color:#2F92EE;'>#厄洛替尼#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36915, encryptionId=f19136915a9, topicName=厄洛替尼)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/6F20312C71B4B22F603078C6DCFA72CE/100, createdBy=d3572500071, createdName=ms306040998833292, createdTime=Fri Jun 03 13:20:00 CST 2011, time=2011-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1410772, encodeId=64241410e728f, content=<a href='/topic/show?id=a4ed130e7d0' target=_blank style='color:#2F92EE;'>#NSCLC患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13077, encryptionId=a4ed130e7d0, topicName=NSCLC患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=06332789533, createdName=xiongliangxl, createdTime=Fri Jun 03 13:20:00 CST 2011, time=2011-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1416240, encodeId=7fbd14162407f, content=<a href='/topic/show?id=6cef59801ea' target=_blank style='color:#2F92EE;'>#晚期NSCLC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59801, encryptionId=6cef59801ea, topicName=晚期NSCLC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3b093156350, createdName=经常头晕, createdTime=Fri Jun 03 13:20:00 CST 2011, time=2011-06-03, status=1, ipAttribution=)]
    2012-01-21 jklm09
  3. [GetPortalCommentsPageByObjectIdResponse(id=1864331, encodeId=5dff1864331dc, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Fri Sep 09 06:20:00 CST 2011, time=2011-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2068914, encodeId=a69720689146d, content=<a href='/topic/show?id=bbd816043f2' target=_blank style='color:#2F92EE;'>#SCLC患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16043, encryptionId=bbd816043f2, topicName=SCLC患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Sat Jan 21 05:20:00 CST 2012, time=2012-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1332052, encodeId=7033133205207, content=<a href='/topic/show?id=f19136915a9' target=_blank style='color:#2F92EE;'>#厄洛替尼#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36915, encryptionId=f19136915a9, topicName=厄洛替尼)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/6F20312C71B4B22F603078C6DCFA72CE/100, createdBy=d3572500071, createdName=ms306040998833292, createdTime=Fri Jun 03 13:20:00 CST 2011, time=2011-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1410772, encodeId=64241410e728f, content=<a href='/topic/show?id=a4ed130e7d0' target=_blank style='color:#2F92EE;'>#NSCLC患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13077, encryptionId=a4ed130e7d0, topicName=NSCLC患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=06332789533, createdName=xiongliangxl, createdTime=Fri Jun 03 13:20:00 CST 2011, time=2011-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1416240, encodeId=7fbd14162407f, content=<a href='/topic/show?id=6cef59801ea' target=_blank style='color:#2F92EE;'>#晚期NSCLC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59801, encryptionId=6cef59801ea, topicName=晚期NSCLC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3b093156350, createdName=经常头晕, createdTime=Fri Jun 03 13:20:00 CST 2011, time=2011-06-03, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1864331, encodeId=5dff1864331dc, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Fri Sep 09 06:20:00 CST 2011, time=2011-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2068914, encodeId=a69720689146d, content=<a href='/topic/show?id=bbd816043f2' target=_blank style='color:#2F92EE;'>#SCLC患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16043, encryptionId=bbd816043f2, topicName=SCLC患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Sat Jan 21 05:20:00 CST 2012, time=2012-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1332052, encodeId=7033133205207, content=<a href='/topic/show?id=f19136915a9' target=_blank style='color:#2F92EE;'>#厄洛替尼#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36915, encryptionId=f19136915a9, topicName=厄洛替尼)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/6F20312C71B4B22F603078C6DCFA72CE/100, createdBy=d3572500071, createdName=ms306040998833292, createdTime=Fri Jun 03 13:20:00 CST 2011, time=2011-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1410772, encodeId=64241410e728f, content=<a href='/topic/show?id=a4ed130e7d0' target=_blank style='color:#2F92EE;'>#NSCLC患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13077, encryptionId=a4ed130e7d0, topicName=NSCLC患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=06332789533, createdName=xiongliangxl, createdTime=Fri Jun 03 13:20:00 CST 2011, time=2011-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1416240, encodeId=7fbd14162407f, content=<a href='/topic/show?id=6cef59801ea' target=_blank style='color:#2F92EE;'>#晚期NSCLC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59801, encryptionId=6cef59801ea, topicName=晚期NSCLC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3b093156350, createdName=经常头晕, createdTime=Fri Jun 03 13:20:00 CST 2011, time=2011-06-03, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1864331, encodeId=5dff1864331dc, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Fri Sep 09 06:20:00 CST 2011, time=2011-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2068914, encodeId=a69720689146d, content=<a href='/topic/show?id=bbd816043f2' target=_blank style='color:#2F92EE;'>#SCLC患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16043, encryptionId=bbd816043f2, topicName=SCLC患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Sat Jan 21 05:20:00 CST 2012, time=2012-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1332052, encodeId=7033133205207, content=<a href='/topic/show?id=f19136915a9' target=_blank style='color:#2F92EE;'>#厄洛替尼#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36915, encryptionId=f19136915a9, topicName=厄洛替尼)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/6F20312C71B4B22F603078C6DCFA72CE/100, createdBy=d3572500071, createdName=ms306040998833292, createdTime=Fri Jun 03 13:20:00 CST 2011, time=2011-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1410772, encodeId=64241410e728f, content=<a href='/topic/show?id=a4ed130e7d0' target=_blank style='color:#2F92EE;'>#NSCLC患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13077, encryptionId=a4ed130e7d0, topicName=NSCLC患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=06332789533, createdName=xiongliangxl, createdTime=Fri Jun 03 13:20:00 CST 2011, time=2011-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1416240, encodeId=7fbd14162407f, content=<a href='/topic/show?id=6cef59801ea' target=_blank style='color:#2F92EE;'>#晚期NSCLC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59801, encryptionId=6cef59801ea, topicName=晚期NSCLC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3b093156350, createdName=经常头晕, createdTime=Fri Jun 03 13:20:00 CST 2011, time=2011-06-03, status=1, ipAttribution=)]

相关资讯

晚期NSCLC一线治疗策略

  7月24日上午,1号会议室的听众们迎来了3位肺癌领域的国外专家。来自英国伯明翰大学医院、伊丽莎白女王医院的卡伦(Cullen)教授、日本仙台东北大学医院的井上(Inoue)助教和德国奥尔登堡皮乌斯医院的格里辛格(Griesinger)教授分别以《晚期非小细胞肺癌(NSCLC)一线治疗的最新进展》、《晚期NSCLC:如何选择化疗还是靶向治疗》和《抗血管生成药物的应用:我们行至何处?》为题,作了大

NCCN非小细胞肺癌临床实践指南

NCCN非小细胞肺癌临床实践指南.pdf

转移性非小细胞肺癌患者的早期姑息治疗

转移性非小细胞肺癌患者的早期姑息治疗 Early Palliative Care for Patients with Metastatic Non-Small-Cell Lung Cancer  Jennifer S. Temel,等 美国波士顿市马萨诸塞总医院等 N Engl J Med 2010;363:733-42. August 19, 2010   背景 转移性非小细胞肺癌病人在

解析2011版《NCCN NSCLC指南》

   美国国家综合癌症网络(NSCLC)临床实践指南是由来自19个国家主要癌症中心的专家, 根据循证医学证据的等级修订和更新NCCN主要肿瘤诊断和治疗指南。NCCN的最大特点是信息全面、及时,筛选科学而又客观。      NCCN指南中国版是由中国抗癌协会与美国NCCN共同,以美国NCCN版本为基础,参照中国临床研究和

2011年版NCCN的NSCLC疾病标准指南

下载: 2011-NCCN-nsclc.pdf   相关资料: 2011版肺腺癌分类新标准出炉 2011版《肺癌诊断及治疗指南》(NICE指南)发布 解析2011版《NCCN NSCLC指南》 2011年版NCCN的NSCLC疾病标准指南 2011nccn小细胞肺癌诊疗指南

肺癌关怀:NCCN指引:先NSCLC病理学检验而后突变测试

国家整合型癌症网络(NCCN)更新的非小细胞肺癌(NSCLC)指引有许多变更,包括再发或转移疾病患者接受全身治疗的评估流程。  NSCLC小组主席、马里兰巴尔的摩约翰霍普金斯悉尼金梅尔整合型癌症中心成员David Ettinger医师表示,该评估流程现在需要在表皮生长因子受体(EGFR)检测之前确定疾病的病理亚型。  病理学检查是重要的!  在再发与转移疾病的情况下,EGFR检测对三种病理疾病亚型